News

Currie Medical to expand in Norfolk

Currie Medical, a medical device manufacturer, plans to invest $1.22 million to expand its operations in Norfolk, creating an estimated 60 jobs.

Based in Franklin, Tennessee, Currie Medical will lease a 30,000-square-foot building at 3701 E. Virginia Beach Blvd. in Norfolk, where it will house its medical device reprocessing operation and distribution center. Currie has 15 employees in Norfolk and employs about 45 people total between Virginia and Tennessee, according to co-owner Carter Smith. The new facility is expected to be in full operation and fully staffed in the first quarter of 2025, he added.

“Currie Medical is excited to expand our operations into the vibrant business community of Norfolk,” Smith and co-owner Owen Griffin said in a statement. “This region offers us a skilled workforce, strong infrastructure and a supportive environment that fosters growth and innovation in the medical technology sector. With this investment, we are committed to bringing new job opportunities to the area and continuing to develop new solutions in medical device reprocessing. We look forward to contributing to the advancement of health care with our growing Norfolk-based team.”

The Virginia Economic Development Partnership worked with the City of Norfolk and the Hampton Roads Economic Development Alliance to secure the project, and the Virginia Jobs Investment Program will assist Currie Medical with consultation and funding for recruitment and training activities. The company is also eligible for state benefits through the Port of Virginia Economic and Infrastructure Development Zone Grant Program.

“Currie Medical’s expansion in Norfolk highlights Virginia’s growing prowess in specialized manufacturing,” Gov. Glenn Youngkin said in a statement. “This project not only adds to our skilled workforce but also strengthens our reputation as a hub for innovative medical technology solutions. We are proud to have them in the commonwealth for years to come.”

Read more here.

Recent News

10/16/2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist. Dr. Rubenstein will lead the Company’s research and scientific strategy, including the continued development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed for the …

10/13/2026

ISOThrive Final Phase 2 Results for MHS-1031 Announced at ACG 2026 Demonstrate Statistically Significant and Clinically Meaningful Improvement in Heartburn Frequency and Severity in NERD PPI-Partial Responders

ISOThrive Inc. announced final results from its Phase 2 trial of MHS-1031 in patients with non-erosive reflux disease (NERD) who experience an incomplete response to proton pump inhibitors (PPIs). Peter Swann, MD, Chief Medical Officer of ISOThrive, and David Johnson, MD MACG FASGE VGSF MACP, Professor of Medicine and Chief of Gastroenterology at Eastern Va …

10/13/2026

Virginia Western and Radford University sign 3 new agreements to create seamless transfer for medical laboratory science degree

Virginia Western Community College and Radford University celebrated a strengthened partnership on Monday, Oct. 12, that will enable seamless transfer for students in three health-related programs. Virginia Western President Laura J. Treanor and Radford President Bret Danilowicz signed the articulation agreements in a ceremony on the Virginia Western campus. Virginia Western students who meet all requirements and complete …